Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Comment by Tropicalsunon Nov 25, 2022 2:55pm
167 Views
Post# 35128815

RE:$180M+ run rate pending

RE:$180M+ run rate pending
HatrikSeLaine wrote: Personally I think it would be very irresponsible of management to not give new guidance if they felt the 180M+ run rate was in jeopardy.   This leads me to believe that this will be the result in the pending financials.  Management probably feels that this target is obtainable through; organic growth, squeezing Margin out of recent acquisitions and clearance of more venitilator set up backlogs.


As I posted back on November the 18th. During a conversation with the Quipt IR person, the question was asked about the forecasted revenue run rate of 180-190 million. His response was that company has not changed their guidance, I guess that doesn't mean it can't still happen.

Wait and see at this point, I am expecting the year end earnings report to be released mid to end of December / 2022.
<< Previous
Bullboard Posts
Next >>